company background image
ZA8 logo

Zymeworks DB:ZA8 Stock Report

Last Price

€11.70

Market Cap

€783.2m

7D

10.4%

1Y

20.9%

Updated

16 Mar, 2025

Data

Company Financials +

ZA8 Stock Overview

A clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. More details

ZA8 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Zymeworks Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zymeworks
Historical stock prices
Current Share PriceUS$11.70
52 Week HighUS$14.80
52 Week LowUS$7.40
Beta1.13
1 Month Change-13.97%
3 Month Change-5.65%
1 Year Change20.87%
3 Year Change91.33%
5 Year Change-50.84%
Change since IPO9.04%

Recent News & Updates

Recent updates

Shareholder Returns

ZA8DE BiotechsDE Market
7D10.4%3.1%-0.5%
1Y20.9%-6.0%15.5%

Return vs Industry: ZA8 exceeded the German Biotechs industry which returned -5.8% over the past year.

Return vs Market: ZA8 exceeded the German Market which returned 15.5% over the past year.

Price Volatility

Is ZA8's price volatile compared to industry and market?
ZA8 volatility
ZA8 Average Weekly Movement8.4%
Biotechs Industry Average Movement9.3%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: ZA8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: ZA8's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2003283Ken Galbraithwww.zymeworks.com

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.

Zymeworks Inc. Fundamentals Summary

How do Zymeworks's earnings and revenue compare to its market cap?
ZA8 fundamental statistics
Market cap€783.19m
Earnings (TTM)-€112.74m
Revenue (TTM)€70.12m

11.2x

P/S Ratio

-6.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZA8 income statement (TTM)
RevenueUS$76.30m
Cost of RevenueUS$136.50m
Gross Profit-US$60.19m
Other ExpensesUS$62.50m
Earnings-US$122.69m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.76
Gross Margin-78.89%
Net Profit Margin-160.80%
Debt/Equity Ratio0%

How did ZA8 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 12:18
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zymeworks Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Arlinda LeeCanaccord Genuity
Yigal NochomovitzCitigroup Inc